Generic Lovenox shows US/EU split on data requirements
This article was originally published in Scrip
The US approval of Sandoz' generic version of Sanofi-Aventis' antithrombotic Lovenox (enoxaparin sodium) raises a number of questions, not least why the FDA sees the product as a generic while for the European authorities a low molecular weight heparin (LMWH) is a biosimilar drug requiring clinical trials for approval.
You may also be interested in...
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.